human pluripotent stem cells (hPSCs), which include human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), have emerged as promising candidates for cell therapy since they have clear target cell differentiation capacity as well as paracrine effects. Advances in the technologies of hiPSC generation without viruses have heightened the expectations for its clinical use.
Fully defined, xenogeneic ingredient-free methods.
High efficiency and standardization of protocol. Reduced production cost and commercialization.
We developed unique system to yield highly purified ECs.
Highly pure differentiated ECs lack of aberrant tissue or tumor development.
Human iPSCs and hiPSC-ECs are generated following guidelines established by the FDA/CBER to ensure the safety of the products and expedite the time for clinical transition. This product has conceptual, technological, scientific and clinical novelty.
We have developed a unique system to differentiate hPSCs into highly purified functional ECs for clinical use including:
We developed a differentiation system to produce hPSC-ECs to improve the efficiency of differentiation and demonstrated a direct vascular-incorporation of hPSC-ECs into blood vessels in animal models.
Favorable effects of hiPSC-ECs on recovery in: